NASDAQ:BIOT Biotech Acquisition (BIOT) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free BIOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.14▼$10.1950-Day Range$10.08▼$10.3252-Week Range$8.30▼$10.41Volume44,400 shsAverage Volume244,605 shsMarket Capitalization$291.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biotech Acquisition alerts: Email Address Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Biotech Acquisition Stock (NASDAQ:BIOT)Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Read More Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. BIOT Stock News HeadlinesMarch 27, 2024 | marketwatch.comBiotech Group Acquisition Withdraws IPOMarch 26, 2024 | wsj.comM&A Gathers Steam for Biotech StartupsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | fool.com.auWhy this exciting ASX biotech stock could be a future starMarch 21, 2024 | bizjournals.comZoning barriers and limited space: How biotech can expand on L.A.'s WestsideMarch 19, 2024 | bizjournals.comPureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders.March 19, 2024 | bizjournals.comAstraZeneca bets $2B on Canada-Boston biotechMarch 19, 2024 | markets.businessinsider.comUK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma AcquisitionMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 19, 2024 | finanznachrichten.deGlobalInvestmentDaily.com: The Next Great Biotech Boom Has ArrivedMarch 19, 2024 | msn.comAstraZeneca agrees to acquire biotech group Fusion for up to $2.4bnMarch 19, 2024 | ft.comAstraZeneca strikes $2.4bn deal for radiotherapy biotech FusionMarch 19, 2024 | benzinga.comAstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer TreatmentsMarch 18, 2024 | markets.businessinsider.comEQS-News: Medios acquires Dutch market leader in pharmaceutical compounding servicesMarch 18, 2024 | markets.businessinsider.comEQS-Adhoc: Medios acquires Dutch market leader in pharmaceutical compounding servicesMarch 15, 2024 | markets.businessinsider.comAssessing Vir Biotechnology: Insights From 5 Financial AnalystsMarch 15, 2024 | finanznachrichten.deAgrinam Acquisition Corporation Provides Update on Qualifying AcquisitionMarch 14, 2024 | msn.comEris Lifesciences enters Rs 30,000 cr injectables market with Biocon Biologics acquisitionMarch 14, 2024 | thetimes.co.ukAstraZeneca buys French biotech for $1bn to boost pipelineMarch 14, 2024 | msn.comAstrazeneca: Pharma giant snaps up rare disease biotech firm AmoyltMarch 13, 2024 | finance.yahoo.comPharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory BoardMarch 12, 2024 | finance.yahoo.comBranded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.March 11, 2024 | bizjournals.comCatalent slashes 90 Bay Area jobs after acquisitionMarch 11, 2024 | finance.yahoo.com20 Highest Paying Countries for BiotechnologyMarch 10, 2024 | fool.com.auBuy this ASX 200 biotech stock for a 20%+ returnMarch 8, 2024 | finance.yahoo.com10 Biotech Stocks with Huge PotentialMarch 7, 2024 | msn.comProtein design pioneer David Baker on why sharing code is key to building biotech startupsSee More Headlines Receive BIOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOT CUSIPN/A CIK1825413 Webbioacq.com Phone212-227-1905FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.22% Return on Assets3.48% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-10.68Miscellaneous Outstanding Shares28,750,000Free Float23,288,000Market Cap$291.81 million OptionableNot Optionable Beta-0.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Michael Shleifer Ph.D. (Age 48)Chairman & CEO Mr. Thomas Fratacci (Age 44)CFO & Treasurer Mr. Ivan Jarry (Age 44)Chief Operating Officer Mr. Albert F. Hummel M.B.A. (Age 76)Chief Investment Officer & Director Key CompetitorsNanobiotixNASDAQ:NBTXVerastemNASDAQ:VSTMAC ImmuneNASDAQ:ACIURAPT TherapeuticsNASDAQ:RAPTAtai Life SciencesNASDAQ:ATAIView All Competitors This page (NASDAQ:BIOT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotech Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.